Fluorometholone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fluorometholone: From Inflammatory Conjunctivitis to Postinfectious Vasculitis
One-Sentence Summary
Fluorometholone is a topical ophthalmic corticosteroid established for treating inflammatory conjunctivitis. The TxGNN model predicts it may be effective for Postinfectious Vasculitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model-generated signal with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory conjunctivitis (per DrugBank pharmacology data; formal Taiwan-approved indication text not yet retrieved) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed official mechanism-of-action (MOA) data has not yet been retrieved from TFDA (data gap DG002). Based on available DrugBank pharmacology annotations, fluorometholone is a synthetic fluorinated corticosteroid that acts as a glucocorticoid receptor (NR3C1) agonist, and its established clinical use is topical anti-inflammatory treatment of inflammatory conjunctivitis.
Postinfectious vasculitis, however, is a systemic inflammatory blood-vessel disease that typically requires systemic immunomodulatory treatment. Fluorometholone is formulated and used exclusively as a topical ophthalmic drug with very low systemic absorption. This creates a categorical mismatch between the drug’s actual delivery route/exposure profile and the systemic reach a vasculitis indication would require.
Given this mismatch, the mechanistic plausibility of this specific prediction is weak. The high TxGNN score (99.91%) reflects a strong pattern-based signal from the knowledge graph, but it is not corroborated by any clinical trial or published literature — this is why the evidence level is rated L5 (model prediction only). Notably, within this same candidate set, rank #2 (“post-bacterial disorder”) has a materially stronger evidentiary basis, including an active Phase 2 trial testing fluorometholone directly (see Conclusion).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Fluorometholone is currently not approved/marketed in Taiwan (0 registrations on file); no license records are available to summarize.
Safety Considerations
- Drug Interactions: DDInter flags 11 potential interacting drugs (Doxycycline, Salbutamol, Cyclosporine, Acetaminophen, Digoxin, Brimonidine, Cephalexin, Alendronic acid, Acyclovir, Diazepam, Fenofibrate). All are recorded with severity level “Unknown” — the interaction is flagged in the database but not yet mechanistically or clinically characterized, so each would need individual review before co-administration decisions are made.
Please refer to the package insert for other safety information (key warnings and contraindications data are not yet available — TFDA label retrieval is a blocking data gap, DG001).
Conclusion and Next Steps
Decision: Hold
Rationale: The postinfectious vasculitis prediction has no clinical trial or literature support (L5, model-only), and the proposed systemic indication is mechanistically inconsistent with fluorometholone’s topical, low-systemic-absorption profile. The drug is also not currently marketed in Taiwan, and TFDA safety labeling data needed for a Stage 1 safety review is still missing (DG001, blocking).
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — currently a blocking data gap
- Confirmed official MOA documentation (DrugBank query pending, DG002)
- Preclinical or mechanistic data establishing a plausible systemic exposure pathway relevant to vasculitis
- Consider redirecting evaluation effort toward “post-bacterial disorder” (rank #2 in this same candidate set), which has a materially stronger evidence base — one completed Phase NA trial (n=154) and one enrolling Phase 2 trial (NCT07308938, n=174) directly testing topical fluorometholone as adjunct anti-inflammatory therapy for bacterial corneal ulcers/post-surgical inflammation, rated evidence level L2.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.